Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
Clinical trial NCT03284424 · COMPLETED
Trial details
- NCT number
- NCT03284424
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-26
- Primary completion
- 2020-07-29
- Enrollment
- 159
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.